Organigram Global (OGI) Operating Leases (2023 - 2024)
Organigram Global (OGI) posted quarterly Operating Leases of $2.5 million for Q3 2024, down 28.0% year-on-year from $3.4 million in Q4 2023, and down 28.0% on a QoQ basis from $3.4 million in Q3 2023.
Organigram Global (OGI) Operating Leases (2023 - 2024) Analysis & Trends
Organigram Global (OGI) has reported Operating Leases for 2 consecutive years, with $2.5 million the latest figure, recorded in Q3 2024.
- Quarterly Operating Leases fell 28.0% year-over-year to $2.5 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $2.5 million (down 28.0% YoY) and the FY2024 annual result came in at $2.5 million, down 27.58% from the prior year.
- Operating Leases eased to $2.5 million in Q3 2024 per OGI's latest filing, from $3.4 million in the prior quarter.
- Over the last five years, Operating Leases for OGI reached as high as $3.4 million in Q3 2023 and fell as low as $2.5 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.45 Mn |
| Sep 30, 2023 | 3.40 Mn |